Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood cancer journal (New York) 2024-02, Vol.14 (1), p.32-32, Article 32
Hauptverfasser:	Badar, Talha, Nanaa, Ahmad, Atallah, Ehab, Shallis, Rory M., Guilherme, Sacchi de Camargo Correia, Goldberg, Aaron D., Saliba, Antoine N., Patel, Anand, Bewersdorf, Jan P., DuVall, Adam S., Bradshaw, Danielle, Abaza, Yasmin, Murthy, Guru Subramanian Guru, Palmisiano, Neil, Zeidan, Amer M., Kota, Vamsi, Litzow, Mark R.
Format:	Artikel
Sprache:	eng
Schlagworte:	692/308/174 692/699/1541/1990/283/1897 Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomedical and Life Sciences Biomedicine Bridged Bicyclo Compounds, Heterocyclic - pharmacology Bridged Bicyclo Compounds, Heterocyclic - therapeutic use Cancer Research Correspondence Hematology Humans Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - pathology Oncology Sulfonamides - pharmacology Sulfonamides - therapeutic use Tumor Suppressor Protein p53 - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!